# Tyme Technologies
 (stock symbol: TYME) Logo in transparent PNG format

## Tyme Technologies
 Logo large

### Tyme Technologies
 Logo large Download PNG (25.15 KB)

![Tyme Technologies
 Logo large Download PNG (25.15 KB)](/img/orig/TYME_BIG-d2749821.png)

## Tyme Technologies
 Logo icon format

### Tyme Technologies
 Logo icon format Download PNG (57.96 KB)

![Tyme Technologies
 Logo icon format Download PNG (57.96 KB)](/img/orig/TYME-26c7075b.png)

## About Tyme Technologies


Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

1. Website domain: tymeinc.com
2. Employees: 13
3. Marketcap: $53.5 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
